297 related articles for article (PubMed ID: 33664848)
1. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
[No Abstract] [Full Text] [Related]
2. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
3. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis.
Shi H; Sun X; Wu Y; Cui Q; Sun S; Ji N; Liu Y
J Clin Neurosci; 2024 Jun; 124():36-46. PubMed ID: 38642434
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
5. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
Marcelis L; Antoranz A; Delsupehe AM; Biesemans P; Ferreiro JF; Debackere K; Vandenberghe P; Verhoef G; Gheysens O; Cattoretti G; Bosisio FM; Sagaert X; Dierickx D; Tousseyn T
Cancer Immunol Immunother; 2020 Sep; 69(9):1751-1766. PubMed ID: 32335702
[TBL] [Abstract][Full Text] [Related]
6. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.
Takashima Y; Kawaguchi A; Sato R; Yoshida K; Hayano A; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Nakano M; Ogawa S; Tashiro K; Yamanaka R
Sci Rep; 2019 Jul; 9(1):10004. PubMed ID: 31292525
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
9. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.
Gandhi MK; Hoang T; Law SC; Brosda S; O'Rourke K; Tobin JWD; Vari F; Murigneux V; Fink L; Gunawardana J; Gould C; Oey H; Bednarska K; Delecluse S; Trappe RU; Merida de Long L; Sabdia MB; Bhagat G; Hapgood G; Blyth E; Clancy L; Wight J; Hawkes E; Rimsza LM; Maguire A; Bojarczuk K; Chapuy B; Keane C
Blood; 2021 Mar; 137(11):1468-1477. PubMed ID: 33202420
[TBL] [Abstract][Full Text] [Related]
10. STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma.
Yang X; Wang Y; Sun X; Bai X; Cui Q; Zhu H; Qian J; Chen Y; Sun S; Ji N; Liu Y
World Neurosurg; 2020 Feb; 134():e1077-e1084. PubMed ID: 31778838
[TBL] [Abstract][Full Text] [Related]
11. Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.
Sun X; Wang C; Chen C; Huang J; Wu X; Wang Y; He X; Cao J; Jiang W; Sun P; Li Z
Hematol Oncol; 2021 Dec; 39(5):625-638. PubMed ID: 34543472
[TBL] [Abstract][Full Text] [Related]
12. Expression of Tim-1 in primary CNS lymphoma.
Kishimoto W; Nishikori M; Arima H; Miyoshi H; Sasaki Y; Kitawaki T; Shirakawa K; Kato T; Imaizumi Y; Ishikawa T; Ohno H; Haga H; Ohshima K; Takaori-Kondo A
Cancer Med; 2016 Nov; 5(11):3235-3245. PubMed ID: 27709813
[TBL] [Abstract][Full Text] [Related]
13. Molecular and clinical diversity in primary central nervous system lymphoma.
Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
[TBL] [Abstract][Full Text] [Related]
14. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma.
Komohara Y; Horlad H; Ohnishi K; Ohta K; Makino K; Hondo H; Yamanaka R; Kajiwara K; Saito T; Kuratsu J; Takeya M
J Clin Exp Hematop; 2011; 51(2):93-9. PubMed ID: 22104307
[TBL] [Abstract][Full Text] [Related]
15. High levels of Tim-3
Zhong W; Liu X; Zhu Z; Li Q; Li K
Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956
[TBL] [Abstract][Full Text] [Related]
16. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
Takashima Y; Kawaguchi A; Iwadate Y; Hondoh H; Fukai J; Kajiwara K; Hayano A; Yamanaka R
PLoS One; 2020; 15(2):e0229577. PubMed ID: 32101576
[TBL] [Abstract][Full Text] [Related]
17. Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression.
Yuan J; Gu K; He J; Sharma S
Hum Pathol; 2013 Apr; 44(4):606-11. PubMed ID: 23089492
[TBL] [Abstract][Full Text] [Related]
18. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.
Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
[TBL] [Abstract][Full Text] [Related]
19. Emerging insights into origin and pathobiology of primary central nervous system lymphoma.
You H; Wei L; Kaminska B
Cancer Lett; 2021 Jul; 509():121-129. PubMed ID: 33766752
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma: a clinicopathological study of 75 cases.
Preusser M; Woehrer A; Koperek O; Rottenfusser A; Dieckmann K; Gatterbauer B; Roessler K; Slavc I; Jaeger U; Streubel B; Hainfellner JA; Chott A
Pathology; 2010; 42(6):547-52. PubMed ID: 20854073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
